PL2211873T3 - Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów - Google Patents

Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów

Info

Publication number
PL2211873T3
PL2211873T3 PL08842462T PL08842462T PL2211873T3 PL 2211873 T3 PL2211873 T3 PL 2211873T3 PL 08842462 T PL08842462 T PL 08842462T PL 08842462 T PL08842462 T PL 08842462T PL 2211873 T3 PL2211873 T3 PL 2211873T3
Authority
PL
Poland
Prior art keywords
amino acids
calcium carbonate
amorphous calcium
phosphorylated amino
stable amorphous
Prior art date
Application number
PL08842462T
Other languages
English (en)
Inventor
Shmuel Bentov
Amir Sagi
Amir Berman
Assaf Shechter
Original Assignee
Amorphical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL186850A external-priority patent/IL186850A/en
Priority claimed from IL193461A external-priority patent/IL193461A/en
Application filed by Amorphical Ltd filed Critical Amorphical Ltd
Publication of PL2211873T3 publication Critical patent/PL2211873T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
PL08842462T 2007-10-22 2008-10-22 Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów PL2211873T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL186850A IL186850A (en) 2007-10-22 2007-10-22 Steady amorphous calcium carbonate containing phosphorylated amino acids, phosphorylated synthetic peptides and gastric proteins
IL193461A IL193461A (en) 2008-08-14 2008-08-14 Stable amorphous calcium carbonate containing phosphorylated amino acids and the use of pharmaceutical and nutritional preparations
PCT/IL2008/001362 WO2009053967A1 (en) 2007-10-22 2008-10-22 Stable amorphous calcium carbonate comprising phosphorylated amino acids, synthetic phosphorylated peptides, and gastrolith proteins
EP08842462A EP2211873B1 (en) 2007-10-22 2008-10-22 Stable amorphous calcium carbonate comprising phosphorylated amino acids

Publications (1)

Publication Number Publication Date
PL2211873T3 true PL2211873T3 (pl) 2013-01-31

Family

ID=40352818

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08842462T PL2211873T3 (pl) 2007-10-22 2008-10-22 Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów

Country Status (9)

Country Link
US (3) US8802160B2 (pl)
EP (2) EP2251018B1 (pl)
JP (2) JP5453283B2 (pl)
CN (2) CN101969962B (pl)
CA (1) CA2703111C (pl)
DK (1) DK2211873T3 (pl)
ES (2) ES2528901T3 (pl)
PL (1) PL2211873T3 (pl)
WO (1) WO2009053967A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2211873T3 (pl) * 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
EP2598579B1 (de) 2010-07-30 2024-09-11 Schaefer Kalk GmbH & Co. KG Kugelförmige, amorphe calciumcarbonat-teilchen
KR101065118B1 (ko) 2011-04-29 2011-09-16 한국지질자원연구원 비정질 탄산칼슘의 형성과 상전이 특성을 분석하는 방법
JP5639551B2 (ja) * 2011-09-13 2014-12-10 株式会社コンカレント 球状炭酸カルシウム微粒子の製造方法
EP2790710B1 (en) * 2011-12-13 2020-08-26 Amorphical Ltd. Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
WO2014024191A1 (en) * 2012-08-07 2014-02-13 Amorphical Ltd. Method for producing stabilized amorphous calcium carbonate
JP2016507553A (ja) * 2013-02-11 2016-03-10 アモーフィカル リミテッド． 骨成長を促進する非晶質炭酸カルシウム
EP3174409A4 (en) 2014-07-31 2018-01-17 Amorphical Ltd. Encapsulated amorphous calcium carbonate compositions
KR101761133B1 (ko) 2015-03-25 2017-07-26 한국지질자원연구원 탄산칼슘 막 코팅방법
US12121538B2 (en) 2015-06-04 2024-10-22 Amorphical Ltd. Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration
HK1253702A1 (zh) 2015-06-04 2019-06-28 艾玛菲克有限公司 用聚磷酸/聚磷酸酯/聚磷酸盐或双膦酸/双膦酸酯/双膦酸盐稳定的无定形碳酸钙
JP6873389B2 (ja) * 2016-01-18 2021-05-19 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
ES3052833T3 (en) 2016-01-18 2026-01-15 Amorphical Ltd Stabilized amorphous calcium carbonate as a supplement for cell culture media
JP7152785B2 (ja) * 2016-10-25 2022-10-13 アモーフィカル リミテッド． 白血病治療のための非晶質炭酸カルシウム
CN108358229B (zh) * 2018-03-12 2021-09-10 兰州生物技术开发有限公司 一种以重组胶原蛋白为生物矿化模板制备微孔CaCO3纳米粒子的方法
CN108888600B (zh) * 2018-07-27 2021-06-08 西北大学 一种基于碳酸钙配位螯合药物的pH敏感纳米药物及制备方法和应用
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
IL289237B2 (en) 2019-07-23 2026-03-01 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance
WO2021072392A1 (en) * 2019-10-10 2021-04-15 The Research Foundation For The State University Of New York Analgesic and anesthetic peptides and other agents
WO2021181372A1 (en) * 2020-03-11 2021-09-16 Amorphical Ltd. Amorphous calcium carbonate for treatment of acidosis
EP4719439A1 (en) * 2023-05-30 2026-04-08 Amorphical Ltd. Amorphous calcium carbonate for prevention and treatment of myocardial ischemia
CN116636494B (zh) * 2023-06-08 2026-04-17 广西壮族自治区水产科学研究院 一种澳洲淡水龙虾同步产卵亲本筛选设备及其筛选方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) * 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4964894A (en) * 1986-03-31 1990-10-23 Freepons Donald E Plant growth regulators derived from chitin
DE3853422T2 (de) * 1988-06-09 1995-10-26 Innogenetics Nv HIV-3-Retrovirus und seine Verwendung.
US6348571B1 (en) * 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
CA2567972C (en) 2004-05-26 2015-07-28 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
SG158153A1 (en) * 2004-12-21 2010-01-29 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
AU2007207429A1 (en) * 2006-01-19 2007-07-26 Warsaw Orthopedic, Inc. Injectable and moldable bone substitute materials
IL178495A (en) * 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
PL2211873T3 (pl) * 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów

Also Published As

Publication number Publication date
CN104530208B (zh) 2018-12-14
JP5453283B2 (ja) 2014-03-26
JP2014061006A (ja) 2014-04-10
US10328100B2 (en) 2019-06-25
US20100310677A1 (en) 2010-12-09
WO2009053967A1 (en) 2009-04-30
EP2251018B1 (en) 2014-12-17
CA2703111C (en) 2016-11-29
EP2251018A3 (en) 2010-11-24
EP2211873B1 (en) 2012-08-08
JP5902145B2 (ja) 2016-04-13
HK1209429A1 (en) 2016-04-01
JP2011501676A (ja) 2011-01-13
CN101969962B (zh) 2014-10-22
EP2211873A1 (en) 2010-08-04
EP2251018A2 (en) 2010-11-17
CN101969962A (zh) 2011-02-09
CA2703111A1 (en) 2009-04-30
US20160045546A1 (en) 2016-02-18
ES2393041T3 (es) 2012-12-18
US8802160B2 (en) 2014-08-12
US20100221362A1 (en) 2010-09-02
ES2528901T3 (es) 2015-02-13
DK2211873T3 (da) 2012-11-19
CN104530208A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
PL2211873T3 (pl) Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
TWI367954B (en) Evaporation source
ZA200905945B (en) Amino Phosphine
IL202473A0 (en) Substituted benzoylamino-indan-2-carboxylic acids and related compounds
EP2116238A4 (en) Amino acid composition
PL2262793T3 (pl) Formy krystaliczne nilotynibu HCL
PL2134652T3 (pl) Kuliste cząstki węglanu wapnia
GB0809360D0 (en) Calcium modulation
EP2094186A4 (en) ANCHORING STAPLES FOR DENTAL IMPLANT
ZA200904053B (en) Phosphonate compounds
GB0702458D0 (en) Salts 668
IL197327A0 (en) Crystalline rosuvastatin calcium
GB0702459D0 (en) Salts 669
EP2155183A4 (en) AMINO ACID DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
ZA200904423B (en) Crystalline forms GLYT 1
IL212442A (en) Calcium carbonate tablets with improved stable mass
GB0613692D0 (en) Benzodiazepine salts
IL177762A0 (en) Bimatoprost crystalline form i
EP2117352A4 (en) NATURAL SALAD SET
ZA201100080B (en) Biomaterials containing calcium phosphate
EP1960057A4 (en) SURFACE ACTIVE CALCIUM PHOSPHATES
LT2040576T (lt) Individualiai suformuota avalynė
GB0715712D0 (en) Amino acid derivatives
GB0624084D0 (en) Ramipril amino acid salts
GB0715626D0 (en) Crystalline form of zofenopril calcium